|
|
| Line 1: |
Line 1: |
| '''Adjuvant therapy'''<ref name=hemonc>Peter Yang and Jeremy Warner. Melanoma. Hemonc.org. Accessed on August 21, 2015. http://hemonc.org/wiki/Melanoma</ref>
| | {{#widget:Quality1}} |
| # Interferon alfa-2a (Roferon-A)
| |
| # Interferon alfa-2b (Intron-A)
| |
| # Peginterferon alfa-2b (Sylatron)
| |
| | |
| '''Metastatic or unresectable disease'''<ref name=hemonc>Peter Yang and Jeremy Warner. Melanoma. Hemonc.org. Accessed on August 21, 2015. http://hemonc.org/wiki/Melanoma</ref>
| |
| :* ''Single Agent Chemotherapy''
| |
| ::# Dabrafenib (Tafinlar)
| |
| ::# Dacarbazine (DTIC)
| |
| ::# Docetaxel (Taxotere)
| |
| ::# High-dose (HD) IL-2
| |
| ::# IL-2 maintenance biotherapy
| |
| ::# Imatinib (Gleevec)
| |
| ::# Ipilimumab (Yervoy)
| |
| ::# Nivolumab (Opdivo) | |
| ::# Paclitaxel (Taxol)
| |
| ::# Pembrolizumab (Keytruda)
| |
| ::# Temozolomide (Temodar)
| |
| ::# Trametinib (Mekinist)
| |
| ::# Vemurafenib (Zelboraf)
| |
| | |
| :* ''Combination Chemotherapy''
| |
| ::# Paclitaxel nanoparticle albumin-bound + Bevacizumab + Carboplatin (ABC)
| |
| ::# Carboplatin + Paclitaxel (CP)
| |
| ::# Carboplatin + Paclitaxel + nanoparticle albumin-bound
| |
| ::# Carboplatin + Paclitaxe +, Sorafenib
| |
| ::# Cisplatin + Dacarbazine ± Carmustine
| |
| ::# Cisplatin + Dacarbazine + IL-2 + IFN alfa-2b ± Carmustine
| |
| ::# Cisplatin + Paclitaxel + Dacarbazine
| |
| ::# Cisplatin + Vinblastine + Dacarbazine (CVD)
| |
| ::# CVD + IL-2 + IFN alfa-2b (sequential biochemotherapy)
| |
| ::# Temozolomide + Bevacizumab (TB)
| |
| ::# Dabrafenib + Trametinib
| |
| ::# Ipilimumab + Dacarbazine
| |
| ::# Ipilimumab + Nivolumab
| |